Highly sensitive analysis for N-myc amplification in neuroblastoma based on fluorescence in situ hybridization

Tajiri, Tatsurou; Shono, Katsuhiro; Fujii, Youichi; Noguchi, Shinji; Kinoshita, Yoshiaki; Tsuneyoshi, Masazumi; Suita, Sachiyo

doi:10.1016/s0022-3468(99)90628-0

Cited by 33 publications

(22 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on the International Neuroblastoma Staging System, (17) nine patients had stage 1 tumors, 10 had stage 2 tumors, 13 had stage 3 tumors, 51 had stage 4 tumors, and seven had stage 4S tumors. MYCN amplification, as determined by FISH analysis of formalin-fixed paraffin-embedded tissues or fresh tumor single cells, (18,19) was detected in 22 (24.4%) tumors. All patients with stage 1 tumors were treated with surgery alone, whereas others were treated with a combination of surgery and chemotherapy with or without autologous bone marrow transplantation according to the risk stratification on the guidelines of the Children's Cancer Group.…”

Section: Methodsmentioning

confidence: 99%

Insulin‐like growth factor II mRNA‐binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma

Chen

Jeng

Chang³

et al. 2011

Cancer Science

View full text Add to dashboard Cite

Insulin-like growth factor II mRNA-binding protein 3 (IMP3) has been reported to enhance proliferation and invasion in various cancers. The role of IMP3 on neuroblastoma (NB) is unknown. We aimed to clarify the prognostic significance of IMP3 expression in patients with NB. By microarray analysis, high IMP3 expression was found in patients with poor outcome. IMP3 expression in 90 NB samples was analyzed by immunohistochemical staining to correlate with clinical stages, histology, and patient outcome. Positive IMP3 expression was detected in 52 of 90 patients, and was significantly correlated with undifferentiated histology, advanced stages, MYCN amplification, and poor outcome. In subgroups, positive IMP3 expression could predict an even worse prognosis in patients with advanced disease, with normal MYCN status, or with MYCN amplification (P = 0.005, P = 0.001, and P = 0.033, respectively). The IMP3 expression decreased by induction of differentiation with retinoid acid treatment in SK-N-DZ and SK-N-SH cells in vitro. The invasion ability of NB cells also decreased as IMP3 knockdown by using RNA interference in vitro. In summary, high expression of IMP3 in NB might contribute to the undifferentiated phenotype and invasive behaviors, leading to a poor prognosis. Determining IMP3 expression in NB could help to improve a personalized therapy. (Cancer Sci 2011; 102: 2191-2198 N euroblastoma (NB), a common cancer of early childhood that originates from primitive sympathetic neural precursors, has a remarkable heterogeneity of clinical behaviors ranging from spontaneous regression to rapid progression and death. Therapeutic options are proposed according to the Children's Oncology Group risk stratification criteria based on clinical and biological factors, including clinical stage, MYCN status, age at diagnosis, histology, and ploidy status.(1,2) Treatment strategy, which ranges from observation alone to intensive multimodal therapy, depends on the risk stratification of the patient in one of the three subgroups of low-, intermediate-, and high-risk of death. Although several biological and molecular prognostic factors have been identified, amplification of the MYCN oncogene, which occurs in roughly 20% of primary NB, is one of the most powerful prognostic factors in NB.(3) The co-opting neurotrophin pathways including the neurotrophin receptors (TrkA, TrkB, and TrkC) and their ligands (NGF, BDNF, and neurotrophin-3, respectively), which regulate the differentiation, apoptosis, and growth of neural cells, are also important prognosis-related factors in NB.(4) However, some patients with a normal MYCN copy number still present with clinically aggressive progression similar to those with MYCN-amplified tumors, suggesting that other unfavorable molecules determining inferior survival may exist.(5,6)The insulin-like growth factor II mRNA-binding protein 3 (IMP3), also known as L532S or K homology domain-containing protein overexpressed in cancer (KOC), is a member of the RNA-binding protein family that includes IMP1, IMP2...

show abstract

Section: Methodsmentioning

confidence: 99%

Insulin‐like growth factor II mRNA‐binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma

Chen

Jeng

Chang³

et al. 2011

Cancer Science

View full text Add to dashboard Cite

show abstract

“…20 The MYCN status of the tumor tissue was evaluated by fluorescence in situ hybridization analysis of formalin-fixed, paraffin-embedded tissues or single fresh tumor cells. 21,22 Based on the risk classifications of the Children's Cancer Group, patients were classified into low-, intermediate-, and high-risk groups and were treated with either surgery alone or a combination of multiple modalities, including chemotherapy, radiotherapy, and/or autologous bone marrow transplantation. 23 Mean follow-up after diagnosis was 70.6 months (range, 1 to 204 months), and overall predictive 5-year survival in this cohort was 48.7%.…”

Section: Patients and Treatmentmentioning

confidence: 99%

B4GALNT3 Expression Predicts a Favorable Prognosis and Suppresses Cell Migration and Invasion via β1 Integrin Signaling in Neuroblastoma

Hsu

Che

Liao

et al. 2011

The American Journal of Pathology

View full text Add to dashboard Cite

Neuroblastoma (NB) is the most common extracranial solid tumor in childhood, accounting for 8% to 10% of all pediatric malignancies. 1 This tumor arises from primitive neuroepithelial cells of the neural crest. 2 The behavior of NB is markedly heterogeneous, ranging from highly undifferentiated tumors with very poor outcomes to welldifferentiated benign ganglioneuroma or NB that may spontaneously regress with favorable prognosis. 3 Half of all patients with newly diagnosed NB are in a high-risk subset with poor overall survival despite intensive therapy. Therefore, it is important to develop useful prognostic tools and to understand NB pathogenesis to help design improved NB therapies.Glycosylation is regulated spatiotemporally during development of the nervous system. 4 Altered carbohydrate structures on tumors are often associated with tumor metastasis and progression. Tumor-associated carbohydrate epitopes commonly found in cancers include GM2,

show abstract

“…The distinction of tumor staging was based on the International Neuroblastoma Staging System (22). MYCN status of the tumor tissue was evaluated by fluorescence in situ hybridization analysis of formalin-fixed, paraffin-embedded tissues or fresh tumor single cells (23,24). Patients were treated with surgery only or a combination of multiple modalities including chemotherapy, radiotherapy, and/or autologous bone marrow transplantation according to the patient's risk grouping (25).…”

Section: Patients and Treatmentmentioning

confidence: 99%

Identification of GRP75 as an Independent Favorable Prognostic Marker of Neuroblastoma by a Proteomics Analysis

Hsu¹,

Lee

Juan

et al. 2008

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Neuroblastoma (NB) is a heterogeneous neoplasm. Detailed biological discrimination is critical for the effective treatment of this disease. Because the tumor behavior of NB is closely associated with the histologic state of differentiation, we thus aimed to identify novel differentiation-associated markers of NB with prognostic implication. Experimental Design: A human NB cell line SH-SY5Y was used as a model system to explore potential biomarkers for the differentiation of NB by proteomic analyses. Seventy-two NB tumor tissues were subsequently investigated by immunohistochemistry to validate the correlations between the expression of a novel prognostic marker, various clinicopathologic and biological factors, and patient survival. Results: Using two-dimensional differential gel electrophoresis, we found a total of 24 spots of proteins in SH-SY5Y cells whose expression was enhanced following differentiation. Glucoseregulated protein 75 (GRP75) was unambiguously identified as one of the five proteins that were dramatically up-regulated following differentiation. Immunohistochemical analyses of 72 NB tumor tissues further revealed that positive GRP75 immunostaining is strongly correlated with differentiated histologies (P < 0.001), mass-screened tumors (P = 0.016), and early clinical stages (P < 0.001) but inversely correlated with MYCN amplification (P = 0.010). Univariate and multivariate survival analyses showed that GRP75 expression is an independent favorable prognostic factor. Conclusions: The present findings clearly showed that our proteomics-based novel experimental paradigm could be a powerful tool to uncover novel biomarkers associated with the differentiation of NB. Our data also substantiate an essential role of GRP75 in the differentiation of NB.

show abstract

Highly sensitive analysis for N-myc amplification in neuroblastoma based on fluorescence in situ hybridization

Cited by 33 publications

References 7 publications

Insulin‐like growth factor II mRNA‐binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma

Insulin‐like growth factor II mRNA‐binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma

B4GALNT3 Expression Predicts a Favorable Prognosis and Suppresses Cell Migration and Invasion via β1 Integrin Signaling in Neuroblastoma

Identification of GRP75 as an Independent Favorable Prognostic Marker of Neuroblastoma by a Proteomics Analysis

Contact Info

Product

Resources

About